ICOS-CD3z NFAT-Luc Jurkat
CBP74063
詢 價
索取Protocol
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫
| I. Background | |
| ICOS is a costimulatory molecule of the CD28 cell surface receptor superfamily that is expressed on activated T-cells. ICOS is involved in T-cell responses upon binding with its ligand, ICOSL (also known as B7-H2, CD275), which is normally expressed on B-cells, dendritic cells and monocytes. | |
| II. Description | |
|
ICOS expression confers an activated phenotype and a strong suppressive capacity to intra-tumoral regulatory T-cells. The ICOS/ICOSL pathway is a key target for cancer immunotherapy. |
|
| III. Introduction | |
| Expressed gene: | ICOS |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+800μg/ml Hygromycin B+10μg/ml Blasticidin |
| Mycoplasma Testing: | Negative |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| IV. Representative Data | |
Figure 1. Dose response of Anti-ICOS Ab in ICOS Effector Reporter Cells(C5).
Figure 2. Dose response of Anti-ICOS Ab in ICOS Effector Reporter Cells(C5).
